Trust the Power of
EYLEA—Proven Results
Across All
Approved
Indications1,2

eylea product

EYLEA efficacy and safety is backed by 8 pivotal studies evaluating clinical outcomes in over 3000 patients: VIEW 1 and VIEW 2 (Neovascular [Wet] AMD) at 52 and 96 weeks; VISTA and VIVID (DME and DR in patients with DME) at 52 and 100 weeks; PANORAMA (DR) at 24, 52, and 100 weeks; GALILEO and COPERNICUS (MEfCRVO) at 24 weeks; and VIBRANT (MEfBRVO) at 24 weeks.1,2 When starting a patient on EYLEA, consider the body of evidence demonstrating proven results.

eylea product

Empower your EYLEA
treatment decisions
from the start with
RESULTS
from the 8
pivotal clinical trials1

eylea4u co pay card co pay card

Comprehensive Support
for Your Patients

From ensuring your eligible patients have access to EYLEA, to helping them
navigate the reimbursement, and even guiding you through orders, returns,
and more, we’re here to help.

co pay card

Experience what
certain retinal diseases
can be like
in virtual
reality

A powerful teaching tool to use with your patients and caregivers, this unique app
lets the user experience symptoms of degenerative eye disease, such as diabetic
retinal changes, firsthand in a 360° view. In My Eyes uses virtual reality and
augmented reality to show the impact of vision impairment on everyday situations.

phone in my eyes
  • apple app store
  • google play

A powerful teaching tool to use with your patients and caregivers, this unique app lets the user experience symptoms of degenerative eye disease, such as diabetic retinal changes, firsthand in a 360° view. In My Eyes uses virtual reality and augmented reality to show the impact of vision impairment on everyday situations.

See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. March 2021.
  2. Wykoff CC. Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study. Data presented
    at: Angiogenesis, Exudation and Degeneration Annual Meeting; February 8, 2020; Miami, FL.